Gilead has named former Roche executive Daniel O’Day as CEO. O’Day has spent nearly his entire career at Roche, starting in sales in 1987 and most recently leading the company’s pharmaceutical division. He is tasked with jumpstarting sales of Gilead’s hepatitis C franchise and leading the charge into cancer treatments. (Wall Street Journal)
An investigation into generic price fixing has expanded to at least 16 companies and 300 drugs. The lawsuit is investigating coordinated price increases across generic drugmakers. Companies including Mylan, Teva, and Dr. Reddy’s have all been named in the probe, but have denied wrongdoing. Joseph Nielsen, the assistant attorney general leading the probe, called it “the largest cartel in the history of the United States.” (Washington Post)
Doctors are failing to disclose ties to drugmakers in their medical studies, an investigation has found. The medical journals are also failing to enforce requirements for authors to disclose financial ties. Experts are concerned that doctors paid by drug companies may skew study results in their favor. (ProPublica)
Sanofi and health data analytics company Sema4 have launched a five-year asthma study. It will research nearly 1,200 patients and plans to use connected inhalers to track how the disease affects individuals differently. The companies will also use machine learning to analyze potential triggers of asthma attacks, how the disease works, and the effectiveness of therapies. (FierceBiotech)
Apple has hired Mango Health CEO Jason Oberfest to join its healthcare team. Oberfest will look into opportunities for the technology company in medication adherence. He also has a background in social media and gaming. (CNBC)
